AstraZeneca is a Global, Biopharmaceutical Company with Research and Development at its Core. The AstraZeneca Open Innovation platform has been created to identify and establish mutually beneficial collaborations that will lead to the discovery and development of new medicines. It provides a robust but simple process for link their expertise, experience, resources, and technology with those of external experts and to explore prospective partnerships that accelerate the advancement of medical science and breakthrough therapies for patients. And the postdoctoral academic institutions of the selected researchers will receive funding to support the corresponding researches for up to three years.

2014年10月13日，NIBS邵峰实验室在《eLife》杂志在线发表“A structural mechanism for bacterial autotransporter glycosylation by a dodecameric heptosyltransferase family”的研究论文（http://elifesciences.org/content/early/2014/10/13/eLife.03714）。该研究报道了一个来自于革兰氏阴性菌的七碳糖糖基转移酶家族成员TibC的12聚体的晶体结构以及TibC与底物TibA自转运蛋白的18聚体复合物的冷冻电镜重构模型。

Yu Zhou^1,2, Chao Wu^2,3, Lifeng Zhao² and Niu Huang^1,2,*

Article first published online: 9 JUN 2014